Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
Author
dc.contributor.author
Yoo, Dae Hyun
Author
dc.contributor.author
Prodanovic, Nenad
Author
dc.contributor.author
Jaworski, Janusz
Author
dc.contributor.author
Miranda, Pedro
Author
dc.contributor.author
Ramiterre, Edgar
Author
dc.contributor.author
Lanzon, Allan
Author
dc.contributor.author
Baranauskaite, Asta
Author
dc.contributor.author
Wiland, Piotr
Author
dc.contributor.author
Abud-Mendoza, Carlos
Author
dc.contributor.author
Oparanov, Boycho
Author
dc.contributor.author
Smiyan, Svitlana
Author
dc.contributor.author
Kim, Houng
Author
dc.contributor.author
Lee, Sang Joon
Author
dc.contributor.author
Kim, Suyeon
Author
dc.contributor.author
Park, Won
Admission date
dc.date.accessioned
2019-03-18T11:54:17Z
Available date
dc.date.available
2019-03-18T11:54:17Z
Publication date
dc.date.issued
2017
Cita de ítem
dc.identifier.citation
Annals of the Rheumatic Diseases, Volumen 76, Issue 2, 2018, Pages 355-363
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: Comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study